Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.52 |
| ▸ | VDR | P11473 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.51 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226249 | 0.87 | EPHA2 (0.55) | GPBAR1EPHA2VDRABCC4SLC10A1 | |
| SCHEMBL16299785 | 0.87 | EPHA2 (0.56) | GPBAR1EPHA2VDRABCC4USP2 | |
| SCHEMBL14978143 | 0.86 | USP2 (0.54) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL18629123 | 0.86 | USP2 (0.54) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL18629132 | 0.86 | USP2 (0.54) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL10226251 | 0.86 | GPBAR1 (0.61) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL10226261 | 0.86 | GPBAR1 (0.61) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL24193196 | 0.86 | USP2 (0.53) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL21101187 | 0.86 | USP2 (0.53) | GPBAR1EPHA2VDRUSP2CYP3A4 | |
| SCHEMBL16357781 | 0.86 | USP2 (0.53) | GPBAR1EPHA2VDRUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | GPBAR1 2010/4885EPHA2 538/4885VDR 1584/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | GPBAR1 2010/4885EPHA2 538/4885VDR 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.